Our Story

 

The orphan drug landscape is changing

 

 

The 10th World Orphan Drug Congress is taking place 12th–14th November, 2019 in Barcelona, Spain; and is not an event to be missed.


Now recognised as the largest and most established European orphan drug event, we are once again proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape. The 10th annual event will address the strategic and commercial aspects of bringing new treatments to patients who suffer from rare diseases.

 

For 2019 we will be expanding the meeting further with a dedicated co-conference on Cell & Gene Therapy and even more dedicated content and tracks than ever before on Clinical/Product Development, Market Access & Pricing, Manufacture, Science & Strategy, Pitch & Partner and Precision Medicine. We will also continue the highly popular Pre-Congress Workshops.


We thank our Advisory Board members for their contribution to the agenda in 2018 - and look forward to working together to make 2019 even more successful.

 

 
500+
Attendees
275+
Companies
200+
Speakers
80%
Decision Makers
2
Co-located events
 

 

Advisory Board
 

Wills Hughes-Wilson, Former Senior Vice President, Chief Patient Access Officer, Sobi

Wills Hughes-Wilson
Head of Patient Access & Commercial Planning 
Mereo Biopharma

Professor Michael Linden, Former VP Gene Therapy & Head, GMI, Pfizer

Professor Michael Linden
Former VP Gene Therapy & Head, GMI
Pfizer

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam
Chief Executive Officer  
EURORDIS

Dr Ségolène Aymé, Founder of Orphanet, Emeritus Research Director, INSERM

Dr Ségolène Aymé
Founder of Orphanet, Emeritus Research Director
INSERM

Dr Bruno Sepodes, Chair of COMP, EMA

Dr Bruno Sepodes
Chair of COMP
EMA

Sheela Upadhyaya, Assoc. Director Highly Specialised Technologies, National Institute For Health and Care Excellence

Sheela Upadhyaya
Assoc. Director Highly Specialised Technologies
National Institute For Health and Care Excellence

Alastair Kent, Former Director, Genetic Alliance UK

Alastair Kent
Former Director
Genetic Alliance UK

Dr Carlo Incerti, SVP, Head of Global Medical Affairs, CMO, Genzyme, A Sanofi Company

Dr Carlo Incerti
SVP, Head of Global Medical Affairs, CMO
Genzyme, A Sanofi Company

Dr Mathew Pletcher, Head of Rare Disease Discovery, Roche

Dr Mathew Pletcher
Head of Rare Disease Discovery
Roche

Dr M Ken Kengatharan, Managing Director, Atheneos Capital

M Ken Kengatharan
Managing Partner, Atheneos Ventures and CEO
Auxesia Orion

Birgitte Volck, President Research & Development, AVROBIO

Birgitte Volck
President Research & Development
AVROBIO

Dr Pedro Franco, Former Scientific Administrator, EMA

Dr Pedro Franco 
Former Scientific Administrator 
EMA

Rick Thompson, CEO, Findacure

Rick Thompson 
CEO 
Findacure

Dr Alexander Natz, Secretary General, EUCOPE

Dr Alexander Natz
Secretary General
EUCOPE

Anna Bucsics, Project Advisor, MoCA

Anna Bucsics
Project Advisor
MoCA 

Josie Godfrey, Former Associate Director, NICE

Josie Godfrey
Former Associate Director
NICE

Dr Diego Ardigo, Chair, IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at Chiesi Group

Dr Diego Ardigo
Chair,  IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at  Chiesi Group

Steve Groft, Senior Advisor to Director, National Center for Advancing Translational Sciences (NCATS), NIH

Steve Groft
Senior Advisor to Director
National Center for Advancing Translational Sciences (NCATS), NIH

Durhane Wong-Rieger, Chair of RDI and CEO, CORD

Durhane Wong-Rieger
Chair of  RDI  and CEO,   CORD

Dr Josep Torrent-Farnell, Head of the medicine division, CatSalut

Dr Josep Torrent-Farnell
Head of the medicine division
CatSalut

 

VIEW 2019 SPEAKERS

 

 

World Orphan Drug Congress Conference

World Orphan Drug Congress Conference

World Orphan Drug Congress Conference

World Orphan Drug Congress Conference